Form 4: BioCryst Director Acquires Shares in Lieu of Cash Retainer

Director Theresa Heggie acquired 999 shares of BioCryst Pharmaceuticals Inc. common stock on February 29, 2024, in lieu of a portion of her quarterly board member retainer.

Summary

• On February 29, 2024, Theresa Heggie, a director of BioCryst Pharmaceuticals Inc., acquired 999 shares of common stock.
• The shares were issued in lieu of 50% of her quarterly cash Board Member retainer of $11,250.
• The price per share was $5.63.
• Following the transaction, Ms. Heggie directly owns 51,860 shares of BioCryst Pharmaceuticals Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director taking shares in lieu of cash suggests confidence in the company's stock.

Positives

• Director's decision to take shares instead of cash demonstrates confidence in the company's future.

Industry Context

Directors often receive compensation in the form of stock to align their interests with those of shareholders. This transaction reflects a common practice in corporate governance.

Comparison to Industry Standards

• Stock compensation for board members is a common practice across the pharmaceutical industry.
• Companies like Amgen, Gilead, and Regeneron often include stock options or grants as part of their director compensation packages.
• The specific amount and structure vary based on company size, performance, and board responsibilities.

Related Party Transactions

• The transaction involves a director receiving shares as part of her compensation, which is a related party transaction.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates